hypofractionated radiotherapy in esophageal carcinoma

Phase 2

Recruiting

• Conditions: esophageal cancer.; Malignant neoplasm of esophagus, unspecified; C15.9

• Registration Number: IRCT20210623051676N1
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 43

Inclusion Criteria

carcinoma in thoracic or abdominal esophagus
performance status above or equal to 70% in karnofsky criteria or less or equal to 1 in ECOG criteria
presence of 3rd grade or more dysphasia or disease in T2-T4 N0 M0 or any T N+ M0 stage
consent to the whole treatment program including surgery

Exclusion Criteria

presence of metastatic disease
presence of cervical esophagus
invasion to heart, trachea, bronchus or aorta
dissent to surgery
history of cancer or other diseases that interfere to complete the treatment program

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of pathological response based on tumor necrosis in microscopic examination. Timepoint: 4 weeks after completion of neoadjuvant chemoradiotherapy. Method of measurement: Pathological evaluation.

Secondary Outcome Measures

Name	Time	Method
Scale of dysphagia. Timepoint: before the intervention and after completing treatment. Method of measurement: dysphagia severity scale.